GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Interest Income

Cambium Bio (ASX:CMB) Interest Income : A$0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Cambium Bio's interest income for the twelve months ended in Jun. 2024 was A$0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00 Mil.


Cambium Bio Interest Income Historical Data

The historical data trend for Cambium Bio's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Interest Income Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cambium Bio Semi-Annual Data
Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Cambium Bio Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines